|Bid||9.20 x 800|
|Ask||9.49 x 900|
|Day's range||9.14 - 9.53|
|52-week range||2.89 - 13.65|
|Beta (5Y monthly)||2.11|
|PE ratio (TTM)||N/A|
|Earnings date||29 Mar 2023 - 03 Apr 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.00|
A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.
The consensus price target hints at a 265.3% upside potential for PDS Biotechnology (PDSB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...